Trial Profile

A Single-arm, Prospective Study of HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxaliplatin (Primary) ; Raltitrexed (Primary) ; Surufatinib (Primary) ; Tislelizumab (Primary)
Indications Cholangiocarcinoma
Focus Therapeutic Use
Acronyms REACH-01

Most Recent Events

21 Nov 2024 Planned primary completion date changed from 31 May 2024 to 31 Dec 2024.
21 Nov 2024 Status changed from recruiting to active, no longer recruiting.
06 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com